院長のご挨拶
院長 鬼塚 俊明
精神科は、児童から老年期まで、生物学的な面から心理学的面まで多様な領域の経験が必要です。九州大学精神科は、伝統的に森田療法や行動療法など精神療法でも有名な教室で、入局以降、十分なトレーニングを受けており、心理療法にも精通しています。一方で、一人で経験できることは限られているため、標準治療である治療ガイドラインに精通する必要もあります。現在、精神科治療ガイドライン普及プログラムの研究のコアメンバーに入っており、私は統合失調症のガイドラインに沿って、全国の処方が行われているか検証しています。具体的には、持続性抗精神病薬注射剤が適正に使用されているかを検証しています。このように治療ガイドラインの普及に注力しています。
精神疾患は慢性的経過をたどることが多いのも事実ですが、近年では、前駆期を含む初発患者に対する適切な早期介入により、長期予後が改善されることがわかってきました。私自身は、統合失調症のリカバリーについて、日本の統合失調症治療の主要メンバーとともにその意見をまとめて世界に発信しました（Onitsuka et al., Current concepts, findings, and future research directions toward recovery in schizophrenia. PCN, 2022）。今後も、精神疾患の早期診断･早期介入を目標として積極的な診療活動と啓蒙活動を推進していく所存です。多岐にわたる精神科の問題に対応するために、精度の高い診断と高度な治療が可能な中核機関として、医療機関はもちろん関係諸機関とも密に連携し、地域社会の中で信頼される施設として更に当院を発展させたいと思っています。どうぞよろしくお願いいたします。
令和5年10月1日
近年の業績
1) Kuwabara H, Kojima M, Benner S, Otowa T, Watanabe T, Kuroda M, Owada K, Yassin W, Hamada J, Kano Y, Uno Y, Kushima I, Mori D, Arioka Y, Munesue T, Kasai K, Higashida H, Abe O, Takao H, Wakuda T, Kameno Y, Inoue J, Harada T, Yamauchi A, Ogawa N, Honda N, Kikuchi S, Seto M, Tomita H, Miyoshi N, Matsumoto M, Kawaguchi Y, Kanai K, Ikeda M, Nakamura I, Isomura S, Hirano Y, Onitsuka T, Takahashi N, Nakashima M, Saitsu H, Kondo K, Ikeda M, Iwata N, Shimada M, Sasaki T, Takei N, Ozaki N, Kosaka H, Okada T, Yamasue H. A key gene modulating oxytocin efficacy in autism: genome-wide discovery and verification in randomized controlled trials datasets. Mol Psychiatry. 2026
2) Yamamuro K, Hasegawa N, Arai Y, Hori H, Muraoka H, Horinouchi T, Hashimoto N, Ochi S, Tsuboi T, Yamagata H, Matsumoto J, Ito S, Onitsuka T, Ohi K, Yamada H, Iga JI, Inada K, Watanabe K, Yasui-Furukori N, Hashimoto R. Association Between Psychiatrists' Subjective Clinical Behavior Scores and Objective Quality Indicators Based on Discharge Prescriptions: A Nationwide Multicenter Study Based on the EGUIDE Project. Neuropsychopharmacol Rep. 2026 Jun;46(2):e70110.
3) Onitsuka T, Yasuda Y, Ito S, Matsumoto J, Okada N, Yamamoto M, Ohi K, Takahashi T, Kubota M, Hashimoto N, Takano H, Hasegawa N, Okada G, Yoshimura R, Nakagawa S, Yamasue H, Numata S, Hashimoto R. A Data-Driven Psychiatric Disorder Subtype Defined by Significant Enlarged Ventricles and Cognitive Impairment: A Replication Study. Neuropsychopharmacol Rep. 2026 Mar;46(1):e70078.
4) Ito Y, Yamamoto N, Nakagawa T, Kato R, Murata M, Onitsuka T, Omori T, Kitano T, Motomura E, Dohi K, Okada M. Case Report: Successful rechallenge with clozapine after clozapine‑induced cardiomyopathy in a patient with treatment‑resistant schizophrenia. Asian J Psychiatr. 2026 Mar 12;119:104948.
5) Hashimoto N, Nemoto K, Fukunaga M, Matsumoto J, Okada N, Morita K, Yamamori H, Fujimoto M, Yasuda Y, Koeda M, Kawashima T, Aki M, Sasabayashi D, Fujikane D, Harada K, Yamamoto M, Ishikawa S, Hasegawa N, Ito S, Ohi K, Matsubara T, Hirano Y, Watanabe Y, Yamasue H, Tateno A, Miyata J, Takahashi T, Kawasaki Y, Onitsuka T, Okubo Y, Asai K, Suzuki M, Ozaki N, Kasai K, Hashimoto R; COCORO. Optimizing multi-site schizophrenia differentiation: MRI harmonization with 20 controls per scanner in a study of 3560 subjects across 15 MRI scanners. Prog Neuropsychopharmacol Biol Psychiatry. 2026 Jan 2;144:111607.
6) Nakahara T, Harada Y, Nakayama N, Hashimoto K, Kida N, Onitsuka T, Noda H, Murasugi K, Takimoto Y, Omori W, Sukegawa T, Shiraishi J, Tanaka K, Maesato H, Ueno T. Personalized Prediction of Clozapine Treatment Response Using Therapeutic Drug Monitoring Data in Japanese Patients with Treatment-Resistant Schizophrenia. J Clin Med. 2025 Nov 6;14(21):7892.
7) Hirakawa N, Oribe N, Hirano Y, Togao O, Ishigami K, Onitsuka T, Hirano S, Nakao T. Volume of the amygdala, hippocampus, Heschl's gyrus, and planum temporale in epileptic psychosis. Psychiatry Res Neuroimaging. 2025 Dec;354:112081.
8) Hasegawa N, Muraoka H, Arai Y, Horinouchi T, Yamamuro K, Hashimoto N, Ochi S, Tsuboi T, Kawamata Y, Nakamura T, Yasuda Y, Matsumoto J, Ito S, Onitsuka T, Ohi K, Numata S, Hori H, Inada K, Watanabe K, Yasui-Furukori N, Hashimoto R. Long-Term Impact of EGUIDE Training on Facility-Wide Guideline Adherence Rate in Schizophrenia and Major Depressive Disorder: A Multicenter Study. Neuropsychopharmacol Rep. 2025 Dec;45(4):e70067.
9) Mitoma R, Tamura S, Hirano S, Sung Y, Takai Y, Mitsudo T, Nakao T, Onitsuka T, Hirano Y. Abnormal spontaneous activity and rest-task shift in schizophrenia. Psychiatry Clin Neurosci. 79(10):697-706. 2025.
10) Yasuda Y, Ito S, Matsumoto J, Onitsuka T, Yamamori H, Fujimoto M, Hasegawa N, Ikeda M, Hashimoto R. Clinical Characteristics of Patients with Enlarged Ventricles and Cognitive Impairment (EVCI): Case Series. Neuropsychopharmacol Rep. 2025 Sep;45(3):e70029.
11) Miura K, Yoshida M, Morita K, Fujimoto M, Yasuda Y, Yamamori H, Takahashi J, Miyata S, Okazaki K, Matsumoto J, Toyomaki A, Makinodan M, Hashimoto N, Onitsuka T, Kasai K, Ozaki N, Hashimoto R. Gaze behaviors during free viewing revealed differences in visual salience processing across four major psychiatric disorders: a mega-analysis study of 1012 individuals. Mol Psychiatry. 2025 Apr;30(4):1594-1600.
12) Onitsuka T: New treatment options for negative symptoms in schizophrenia. Psychiatry Clin Neurosci, 79: 1, 2025.
13) Hashimoto N, Okada N, Fukunaga M, Nemoto K, Miura K, Matsumoto J, Ishikawa S, Narita H, Morita K, Yasuda Y, Kamishikiryo T, Harada K, Yamamoto M, Ohi K, Matsubara T, Hirano Y, Okada G, Tha KK, Abe O, Onitsuka T, Kawasaki Y, Ozaki N, Kasai K, Hashimoto R; COCORO. Lithium and valproate affect subcortical brain volumes in individuals with bipolar disorder: Mega-analysis of 235 individuals. J Affect Disord. 381: 115–120, 2025.
14) Yasuda Y, Ito S, Matsumoto J, Okada N, Onitsuka T, Ikeda M, Kushima I, Sumiyoshi C, Fukunaga M, Nemoto K, Miura K, Hashimoto N, Ohi K, Takahashi T, Sasabayashi D, Koeda M, Yamamori H, Fujimoto M, Takano H, Hasegawa N, Narita H, Yamamoto M, Tha KK, Kikuchi M, Kamishikiryo T, Itai E, Okubo Y, Tateno A, Nakamura M, Kubota M, Igarashi H, Hirano Y, Okada G, Miyata J, Numata S, Abe O, Yoshimura R, Nakagawa S, Yamasue H, Ozaki N, Kasai K, Hashimoto R. Proposal for a Novel Classification of Patients With Enlarged Ventricles and Cognitive Impairment Based on Data-Driven Analysis of Neuroimaging Results in Patients With Psychiatric Disorders. Neuropsychopharmacol Rep. 45: e70010, 2025.
15) Ochi S, Tsuboi T, Hasegawa N, Hori H, Ichihashi K, Imamura Y, Okada T, Kodaka F, Saito Y, Iga JI, Onitsuka T, Atake K, Ueno SI, Hashimoto R, Yasui-Furukori N. The association between benzodiazepine prescriptions and the risk of laxative use in schizophrenia treatment. Neuropsychopharmacol Rep. 45: e12499, 2025.
16) Nakamura T, Furihata R, Hasegawa N, Kodaka F, Muraoka H, Ichihashi K, Ochi S, Numata S, Tsuboi T, Makinodan M, Iida H, Onitsuka T, Kashiwagi H, Takeshima M, Hashimoto N, Nagasawa T, Usami M, Yamagata H, Takaesu Y, Miura K, Matsumoto J, Ohi K, Yamada H, Hori H, Inada K, Watanabe K, Hashimoto R, Yasui-Furukori N. The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study. BMC Psychiatry. 24(1): 399, 2024.
17) Morita K, Miura K, Toyomaki A, Makinodan M, Ohi K, Hashimoto N, Yasuda Y, Mitsudo T, Higuchi F, Numata S, Yamada A, Aoki Y, Honda H, Mizui R, Honda M, Fujikane D, Matsumoto J, Hasegawa N, Ito S, Akiyama H, Onitsuka T, Satomura Y, Kasai K, Hashimoto R. Tablet-Based Cognitive and Eye Movement Measures as Accessible Tools for Schizophrenia Assessment: Multisite Usability Study. JMIR Ment Health. 11: e56668, 2024.
18) Takai Y, Tamura S, Hoaki N, Kitajima K, Nakamura I, Hirano S, Ueno T, Nakao T, Onitsuka T, Hirano Y. Aberrant thalamocortical connectivity and shifts between the resting state and task state in schizophrenia. Eur J Neurosci. 59: 1961–1976, 2024.
19) Wakuda T, Benner S, Uemura Y, Nishimura T, Kojima M, Kuroda M, Matsumoto K, Kanai C, Inada N, Harada T, Kameno Y, Munesue T, Inoue J, Umemura K, Yamauchi A, Ogawa N, Kushima I, Suyama S, Saito T, Hamada J, Kano Y, Honda N, Kikuchi S, Seto M, Tomita H, Miyoshi N, Matsumoto M, Kawaguchi Y, Kanai K, Ikeda M, Nakamura I, Isomura S, Hirano Y, Onitsuka T, Ozaki N, Kosaka H, Okada T, Kuwabara H, Yamasue H. Oxytocin-induced increases in cytokines and clinical effect on the core social features of autism: Analyses of RCT datasets. Brain Behav Immun. 118: 398–407, 2024.
20) Onitsuka T: Advancing PTSD treatment: a novel approach in treatment-resistant childhood sexual abuse PTSD. Psychiatry Clin Neurosci, 78: 1, 2024.
21) Onitsuka T: Introduction of the Special Issue on “Neurophysiology/Neuroimaging Study in Japan.” Clin EEG Neurosci, 54: 559, 2023.
22) Okada N, Fukunaga M, Miura K, Nemoto K, Matsumoto J, Hashimoto N, Kiyota M, Morita K, Koshiyama D, Ohi K, Takahashi T, Koeda M, Yamamori H, Fujimoto M, Yasuda Y, Hasegawa N, Narita H, Yokoyama S, Mishima R, Kawashima T, Kobayashi Y, Sasabayashi D, Harada K, Yamamoto M, Hirano Y, Itahashi T, Nakataki M, Hashimoto RI, Tha KK, Koike S, Matsubara T, Okada G, van Erp TGM, Jahanshad N, Yoshimura R, Abe O, Onitsuka T, Watanabe Y, Matsuo K, Yamasue H, Okamoto Y, Suzuki M, Turner JA, Thompson PM, Ozaki N, Kasai K, Hashimoto R. Subcortical volumetric alterations in four major psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification. Mol Psychiatry. 28: 5206–5216, 2023.
23) Matsumoto J, Fukunaga M, Miura K, Nemoto K, Okada N, Hashimoto N, Morita K, Koshiyama D, Ohi K, Takahashi T, Koeda M, Yamamori H, Fujimoto M, Yasuda Y, Ito S, Yamazaki R, Hasegawa N, Narita H, Yokoyama S, Mishima R, Miyata J, Kobayashi Y, Sasabayashi D, Harada K, Yamamoto M, Hirano Y, Itahashi T, Nakataki M, Hashimoto RI, Tha KK, Koike S, Matsubara T, Okada G, Yoshimura R, Abe O, van Erp TGM, Turner JA, Jahanshad N, Thompson PM, Onitsuka T, Watanabe Y, Matsuo K, Yamasue H, Okamoto Y, Suzuki M, Ozaki N, Kasai K, Hashimoto R. Cerebral cortical structural alteration patterns across four major psychiatric disorders in 5549 individuals. Mol Psychiatry. 28: 4915–4923, 2023.
24) Matsumoto R, Motomura E, Onitsuka T, Okada M. Trends in suicidal mortality and motives among working-ages individuals in Japan during 2007–2022. Eur J Investig Health Psychol Educ. 13: 2795–2810, 2023.
25) Onitsuka T, Okada T, Hasegawa N, Tsuboi T, Iga JI, Yasui-Furukori N, Yamada N, Hori H, Muraoka H, Ohi K, Ogasawara K, Ochi S, Takeshima M, Ichihashi K, Fukumoto K, Iida H, Yamada H, Furihata R, Makinodan M, Takaesu Y, Numata S, Komatsu H, Hishimoto A, Kido M, Atake K, Yamagata H, Kikuchi S, Hashimoto N, Usami M, Katsumoto E, Asami T, Kubota C, Matsumoto J, Miura K, Hirano Y, Watanabe K, Inada K, Hashimoto R. Combination psychotropic use for schizophrenia with long-acting injectable antipsychotics and oral antipsychotics: a nationwide real-world study in Japan. J Clin Psychopharmacol. 43: 365–368, 2023.
26) Nakanishi S, Tamura S, Hirano S, Takahashi J, Kitajima K, Takai Y, Mitsudo T, Togao O, Nakao T, Onitsuka T, Hirano Y. Abnormal phase entrainment of low- and high-gamma-band auditory steady-state responses in schizophrenia. Front Neurosci. 17: 1277733, 2023.
27) Hashimoto N, Yasui-Furukori N, Hasegawa N, Ishikawa S, Hori H, Iida H, Ichihashi K, Miura K, Matsumoto J, Numata S, Kodaka F, Furihata R, Ohi K, Ogasawara K, Iga JI, Muraoka H, Komatsu H, Takeshima M, Atake K, Kido M, Nakamura T, Kishimoto T, Hishimoto A, Onitsuka T, Okada T, Ochi S, Nagasawa T, Makinodan M, Yamada H, Tsuboi T, Yamada H, Inada K, Watanabe K, Hashimoto R: Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project. BMC Psychiatry, 23: 473, 2023.
28) Fukumoto K, Kodaka F, Hasegawa N, Muraoka H, Hori H, Ichihashi K, Yasuda Y, Iida H, Ohi K, Ochi S, Ide K, Hashimoto N, Usami M, Nakamura T, Komatsu H, Okada T, Nagasawa T, Furihata R, Atake K, Kido M, Kikuchi S, Yamagata H, Kishimoto T, Makinodan M, Horai T, Takeshima M, Kubota C, Asami T, Katsumoto E, Hishimoto A, Onitsuka T, Matsumoto J, Miura K, Yamada H, Yasui-Furukori N, Watanabe K, Inada K, Otsuka K, Hashimoto R: Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood Disorders. Neuropsychopharmacol Rep, 43: 33-39, 2023.
29) Iida H, Okada T, Nemoto K, Hasegawa N, Numata S, Ogasawara K, Miura K, Matsumoto J, Hori H, Iga JI, Ichihashi K, Hashimoto N, Yamada H, Ohi K, Yasui-Furukori N, Fukumoto K, Tsuboi T, Usami M, Furihata R, Takaesu Y, Hishimoto A, Muraoka H, Katsumoto E, Nagasawa T, Ochi S, Komatsu H, Kikuchi S, Takeshima M, Onitsuka T, Tamai S, Kubota C, Inada K, Watanabe K, Kawasaki H, Hashimoto R: Satisfaction with web-based courses on clinical practice guidelines for psychiatrists: Findings from the "Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)" project. Neuropsychopharmacol Rep, 43: 23-32, 2023.
30) Kitajima K, Tamura S, Sasabayashi D, Nakajima S, Iwata Y, Ueno F, Takai Y, Takahashi J, Caravaggio F, Mar W, Torres-Carmona E, Noda Y, Gerretsen P, Luca V, Mimura M, Hirano S, Nakao T, Onitsuka T, Remington G, Graff-Guerrero A, Hirano Y: Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment-resistant and ultra-treatment-resistant schizophrenia. Psychiatry Clin Neurosci, 77: 2-11, 2023.
31) Onitsuka T, Tsuchimoto R, Oribe N, Spencer KM, Hirano Y: Neuronal imbalance of excitation and inhibition in schizophrenia: a scoping review of gamma-band ASSR findings. Psychiatry Clin Neurosci, 76: 610-619, 2022.
32) Onitsuka T, Hirano Y, Nakazawa T, Ichihashi K, Miura K, Inada K, Mitoma R, Yasui-Furukori N, Hashimoto R: Current concepts, findings, and future research directions toward recovery in schizophrenia. Psychiatry Clin Neurosci, 76: 282-291, 2022.
33) Onitsuka T, Hirano Y, Nemoto K, Hashimoto N, Kushima I, Koshiyama D, Koeda M, Takahashi T, Noda Y, Matsumoto J, Miura K, Nakazawa T, Hikida T, Kasai K, Ozaki N, Hashimoto R: Trends in big data analyses by multicenter collaborative translational research in psychiatry. Psychiatry Clin Neurosci, 76: 1-14, 2022.
34) Tamura S, Hirose N, Mitsudo T, Hoaki N, Nakamura I, Onitsuka T, Hirano Y: Multimodal imaging of the auditory-larynx motor network for voicing perception. NeuroImage, 251:118981. doi: 10.1016/j.neuroimage.2022.118981. 2022.
35) Okamoto H, Onitsuka T, Kuga H, Oribe N, Nakayama N, Fukushima S, Nakao T, Ueno T: Decreased BOLD signals elicited by 40-Hz auditory stimulation of the right primary auditory cortex in bipolar disorder: An fMRI study. Front Psychiatry, 13: 833896, 2022.
36) Yamasue H, Kojima M, Kuwabara H, Kuroda M, Matsumoto K, Kanai C, Inada N, Owada K, Ochi K, Ono N, Benner S, Wakuda T, Kameno Y, Inoue J, Harada T, Tsuchiya K, Umemura K, Yamauchi A Ogawa N, Kushima I, Ozaki N, Suyama S, Saito T, Uemura Y, Kano Y, Honda N, Kikuchi S, Seto M, Tomita H, Miyoshi N, Matsumoto M, Kawaguchi Y, Kanai K, Ikeda M, Nakamura I, Isomura S, Hirano Y, Onitsuka T, Kosaka H, Okada T: Effect of a novel nasal oxytocin spray with enhanced bioavailability on autism: A randomised trial. Brain, 145: 490-499, 2022.
37) Yasui-Furukori N, Muraoka H, Hasegawa N, Ochi S, Numata S, Hori H, Hishimoto A, Onitsuka T, Ohi K, Hashimoto N, Nagasawa T, Takaesu Y, Inagaki T, Tagata H, Tsuboi T, Kubota C, Furihata R, Iga J, Iida H, Miura K, Matsumoto J, Yamada H, Watanabe K, Inada K, Shimoda K, Hashimoto R. Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep, 42:3-9, 2022.
38) Ogasawara K, Numata S, Hasegawa N, Nakataki M, Makinodan M, Ohi K, Takeshima M, Tsuboi T, Hashimoto N, Onitsuka T, Muraoka H, Hori H, Ichihashi K, Inagaki T, Yasui-Furukori N, Hishimoto A, Sugiyama N, Fukumoto K, Nagasawa T, Matsumoto J,Takaesu Y, Furihata R, Nemoto K, Nakamura T, Usami M, Miura K, Fujimoto M,Tagata H, Yamada H, Komatsu H, Ochi S, Atake K, Katsumoto E, Kido M, Kishimoto T, Suwa T, Yamamura S, Iga JI, Iida H, Inada K, Watanabe K, Hashimoto R. Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. Neuropsychopharmacol Rep, 42: 221-225, 2022.
39) Kyou Y, Yasui-Furukori N, Hasegawa N, Ide K, Ichihashi K, Hashimoto N, Hori H, Shimizu Y, Imamura Y, Muraoka H, Iida H, Ohi K, Yasuda Y, Ogasawara K, Numata S, Iga JI, Tsuboi T, Ochi S, Kodaka F, Furihata R, Onitsuka T, Makinodan M, Komatsu H, Takeshima M, Kubota C, Hishimoto A, Atake K, Yamagata H, Kido M, Nagasawa T, Usami M, Kishimoto T, Kikuchi S, Matsumoto J, Miura K, Yamada H, Watanabe K, Inada K, Hahimoto R. The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)" project. Ann Gen Psychiatry. 26;21(1):52, 2022.
40) Yamada H, Motoyama M, Hasegawa N, Miura K, Matsumoto J, Ohi K, Yasui-Furukori N, Numata S, Takeshima M, Sugiyama N, Nagasawa T, Kubota C, Atake K, Tsuboi T, Ichihashi K, Hashimoto N, Inagaki T, Takaesu Y, Iga JI, Hori H, Onitsuka T, Komatsu H, Hishimoto A, Fukumoto K, Fujimoto M, Nakamura T, Nemoto K, Furihata R, Yamamura S, Yamagata H, Ogasawara K, Katsumoto E, Murata A, Iida H, Ochi S, Makinodan M, Kido M, Kishimoto T, Yasuda Y, Usami M, Suwa T, Inada K, Watanabe K, Hashimoto R: A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project. BJPsych Open, 8: e83, 2022.
41) Hori H, Yasui-Furukori N, Hasegawa N, Iga J, Ochi S, Ichihashi K, Furihata R, Kyo Y, Takaesu Y, Tsuboi T, Kodaka F, Onitsuka T, Okada T, Murata A, Kashiwagi H, Iida H, Hashimoto N, Ohi K, Yamada H, Ogasawara K, Yasuda Y, Muraoka H, Usami M, Numata S, Takeshima M, Yamagata H, Nagasawa T, Tagata H, Makinodan M, Kido M, Katsumoto E, Komatsu H, Matsumoto J, Kubota C, Miura K, Hishimoto A, Watanabe K, Inada K, Kawasaki H, Hashimot R. Prescription of anticholinergic drugs in patients with schizophrenia: analysis of antipsychotic prescription patterns and hospital characteristics. Front Psychiatry, 13: 823826, 2022.
42) Muraoka H, Kodaka F, Hasegawa N, Yasui-Furukori N, Fukumoto K, Kashiwagi H, Tagata H, Hori H, Atake K, Iida H, Ichihashi K, Furihata R, Tsuboi T, Takeshima M, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Makinodan M, Nakamura T, Kido M, Ueda I, Yamagata H, Onitsuka T, Asami T, Hishimoto A, Ogasawara K, Katsumoto E, Miura K, Matsumoto J, Ohi K, Yamada H, Watanabe K, Inada K, Nishimura K, Hashimoto R. Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site study. Asian J Psychiatry, 74:103174, 2022.
43) Furihata R, Otsuki R, Hasegawa N, Tsuboi T, Numata S, Yasui-Furukori N, Kashiwagi H, Hori H, Ochi S, Muraoka H, Onitsuka T, Komatsu H, Takeshima M, Hishimoto A, Nagasawa T, Takaesu Y, Nakamura T, Asami T, Miura K, Matsumoto J, Ohi K, Yasuda Y, Iida H, Ogasawara K, Hashimoto N, Ichihashi K, Yamada H, Watanabe K, Inada K, Hashimoto R. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study. Sleep Med, 89:23-30, 2021.
44) Sato J, Hirano Y, Hirakawa N, Takahashi J, Oribe N, Kuga H, Nakamura I, Hirano S, Ueno T, Togao O, Hiwatashi A, Nakao T, Onitsuka T: Lower hippocampal volume in patients with schizophrenia and bipolar disorder: a quantitative MRI study. J Pers Med. 13: 11, 121, 2021.
45) Takahashi J, Hirano Y, Miura K, Morita K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Shishido E, Okazaki K, Shiino T, Nakao T, Kasai K, Hashimoto R, Onitsuka T: Eye movement abnormalities in major depressive disorder. Front Psychiatry. 2021 10: 12, 673443, 2021.
46) Takahashi J, Miura K, Morita K, Fujimoto M, Miyata S, Okazaki K, Matsumoto J, Hasegawa N, Hirano Y, Yamamori H, Yasuda Y, Makinodan M, Kasai K, Ozaki N, Onitsuka T, Hashimoto R: Effects of age and sex on the eye movement characteristics. Neuropsychopharmacol Rep, 41: 152-158, 2021.
47) Numata S, Nakataki M, Hasegawa N, Takaesu Y, Takeshima M, Onitsuka T, Nakamura T, Edagawa R, Edo H, Miura K; Matsumoto J, Yasui-Furukori N, Kishimoto T; Hori H, Tsuboi T, Yasuda Y, Furihata R, Muraoka H, Ochi S, Nagasawa T; Kyou T, Murata A, Katsumoto E, Ohi K, Hishimoto A, Inada K, Watanabe K, Hashimoto R: Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep. 41: 199-206, 2021.
2) Yamamuro K, Hasegawa N, Arai Y, Hori H, Muraoka H, Horinouchi T, Hashimoto N, Ochi S, Tsuboi T, Yamagata H, Matsumoto J, Ito S, Onitsuka T, Ohi K, Yamada H, Iga JI, Inada K, Watanabe K, Yasui-Furukori N, Hashimoto R. Association Between Psychiatrists' Subjective Clinical Behavior Scores and Objective Quality Indicators Based on Discharge Prescriptions: A Nationwide Multicenter Study Based on the EGUIDE Project. Neuropsychopharmacol Rep. 2026 Jun;46(2):e70110.
3) Onitsuka T, Yasuda Y, Ito S, Matsumoto J, Okada N, Yamamoto M, Ohi K, Takahashi T, Kubota M, Hashimoto N, Takano H, Hasegawa N, Okada G, Yoshimura R, Nakagawa S, Yamasue H, Numata S, Hashimoto R. A Data-Driven Psychiatric Disorder Subtype Defined by Significant Enlarged Ventricles and Cognitive Impairment: A Replication Study. Neuropsychopharmacol Rep. 2026 Mar;46(1):e70078.
4) Ito Y, Yamamoto N, Nakagawa T, Kato R, Murata M, Onitsuka T, Omori T, Kitano T, Motomura E, Dohi K, Okada M. Case Report: Successful rechallenge with clozapine after clozapine‑induced cardiomyopathy in a patient with treatment‑resistant schizophrenia. Asian J Psychiatr. 2026 Mar 12;119:104948.
5) Hashimoto N, Nemoto K, Fukunaga M, Matsumoto J, Okada N, Morita K, Yamamori H, Fujimoto M, Yasuda Y, Koeda M, Kawashima T, Aki M, Sasabayashi D, Fujikane D, Harada K, Yamamoto M, Ishikawa S, Hasegawa N, Ito S, Ohi K, Matsubara T, Hirano Y, Watanabe Y, Yamasue H, Tateno A, Miyata J, Takahashi T, Kawasaki Y, Onitsuka T, Okubo Y, Asai K, Suzuki M, Ozaki N, Kasai K, Hashimoto R; COCORO. Optimizing multi-site schizophrenia differentiation: MRI harmonization with 20 controls per scanner in a study of 3560 subjects across 15 MRI scanners. Prog Neuropsychopharmacol Biol Psychiatry. 2026 Jan 2;144:111607.
6) Nakahara T, Harada Y, Nakayama N, Hashimoto K, Kida N, Onitsuka T, Noda H, Murasugi K, Takimoto Y, Omori W, Sukegawa T, Shiraishi J, Tanaka K, Maesato H, Ueno T. Personalized Prediction of Clozapine Treatment Response Using Therapeutic Drug Monitoring Data in Japanese Patients with Treatment-Resistant Schizophrenia. J Clin Med. 2025 Nov 6;14(21):7892.
7) Hirakawa N, Oribe N, Hirano Y, Togao O, Ishigami K, Onitsuka T, Hirano S, Nakao T. Volume of the amygdala, hippocampus, Heschl's gyrus, and planum temporale in epileptic psychosis. Psychiatry Res Neuroimaging. 2025 Dec;354:112081.
8) Hasegawa N, Muraoka H, Arai Y, Horinouchi T, Yamamuro K, Hashimoto N, Ochi S, Tsuboi T, Kawamata Y, Nakamura T, Yasuda Y, Matsumoto J, Ito S, Onitsuka T, Ohi K, Numata S, Hori H, Inada K, Watanabe K, Yasui-Furukori N, Hashimoto R. Long-Term Impact of EGUIDE Training on Facility-Wide Guideline Adherence Rate in Schizophrenia and Major Depressive Disorder: A Multicenter Study. Neuropsychopharmacol Rep. 2025 Dec;45(4):e70067.
9) Mitoma R, Tamura S, Hirano S, Sung Y, Takai Y, Mitsudo T, Nakao T, Onitsuka T, Hirano Y. Abnormal spontaneous activity and rest-task shift in schizophrenia. Psychiatry Clin Neurosci. 79(10):697-706. 2025.
10) Yasuda Y, Ito S, Matsumoto J, Onitsuka T, Yamamori H, Fujimoto M, Hasegawa N, Ikeda M, Hashimoto R. Clinical Characteristics of Patients with Enlarged Ventricles and Cognitive Impairment (EVCI): Case Series. Neuropsychopharmacol Rep. 2025 Sep;45(3):e70029.
11) Miura K, Yoshida M, Morita K, Fujimoto M, Yasuda Y, Yamamori H, Takahashi J, Miyata S, Okazaki K, Matsumoto J, Toyomaki A, Makinodan M, Hashimoto N, Onitsuka T, Kasai K, Ozaki N, Hashimoto R. Gaze behaviors during free viewing revealed differences in visual salience processing across four major psychiatric disorders: a mega-analysis study of 1012 individuals. Mol Psychiatry. 2025 Apr;30(4):1594-1600.
12) Onitsuka T: New treatment options for negative symptoms in schizophrenia. Psychiatry Clin Neurosci, 79: 1, 2025.
13) Hashimoto N, Okada N, Fukunaga M, Nemoto K, Miura K, Matsumoto J, Ishikawa S, Narita H, Morita K, Yasuda Y, Kamishikiryo T, Harada K, Yamamoto M, Ohi K, Matsubara T, Hirano Y, Okada G, Tha KK, Abe O, Onitsuka T, Kawasaki Y, Ozaki N, Kasai K, Hashimoto R; COCORO. Lithium and valproate affect subcortical brain volumes in individuals with bipolar disorder: Mega-analysis of 235 individuals. J Affect Disord. 381: 115–120, 2025.
14) Yasuda Y, Ito S, Matsumoto J, Okada N, Onitsuka T, Ikeda M, Kushima I, Sumiyoshi C, Fukunaga M, Nemoto K, Miura K, Hashimoto N, Ohi K, Takahashi T, Sasabayashi D, Koeda M, Yamamori H, Fujimoto M, Takano H, Hasegawa N, Narita H, Yamamoto M, Tha KK, Kikuchi M, Kamishikiryo T, Itai E, Okubo Y, Tateno A, Nakamura M, Kubota M, Igarashi H, Hirano Y, Okada G, Miyata J, Numata S, Abe O, Yoshimura R, Nakagawa S, Yamasue H, Ozaki N, Kasai K, Hashimoto R. Proposal for a Novel Classification of Patients With Enlarged Ventricles and Cognitive Impairment Based on Data-Driven Analysis of Neuroimaging Results in Patients With Psychiatric Disorders. Neuropsychopharmacol Rep. 45: e70010, 2025.
15) Ochi S, Tsuboi T, Hasegawa N, Hori H, Ichihashi K, Imamura Y, Okada T, Kodaka F, Saito Y, Iga JI, Onitsuka T, Atake K, Ueno SI, Hashimoto R, Yasui-Furukori N. The association between benzodiazepine prescriptions and the risk of laxative use in schizophrenia treatment. Neuropsychopharmacol Rep. 45: e12499, 2025.
16) Nakamura T, Furihata R, Hasegawa N, Kodaka F, Muraoka H, Ichihashi K, Ochi S, Numata S, Tsuboi T, Makinodan M, Iida H, Onitsuka T, Kashiwagi H, Takeshima M, Hashimoto N, Nagasawa T, Usami M, Yamagata H, Takaesu Y, Miura K, Matsumoto J, Ohi K, Yamada H, Hori H, Inada K, Watanabe K, Hashimoto R, Yasui-Furukori N. The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study. BMC Psychiatry. 24(1): 399, 2024.
17) Morita K, Miura K, Toyomaki A, Makinodan M, Ohi K, Hashimoto N, Yasuda Y, Mitsudo T, Higuchi F, Numata S, Yamada A, Aoki Y, Honda H, Mizui R, Honda M, Fujikane D, Matsumoto J, Hasegawa N, Ito S, Akiyama H, Onitsuka T, Satomura Y, Kasai K, Hashimoto R. Tablet-Based Cognitive and Eye Movement Measures as Accessible Tools for Schizophrenia Assessment: Multisite Usability Study. JMIR Ment Health. 11: e56668, 2024.
18) Takai Y, Tamura S, Hoaki N, Kitajima K, Nakamura I, Hirano S, Ueno T, Nakao T, Onitsuka T, Hirano Y. Aberrant thalamocortical connectivity and shifts between the resting state and task state in schizophrenia. Eur J Neurosci. 59: 1961–1976, 2024.
19) Wakuda T, Benner S, Uemura Y, Nishimura T, Kojima M, Kuroda M, Matsumoto K, Kanai C, Inada N, Harada T, Kameno Y, Munesue T, Inoue J, Umemura K, Yamauchi A, Ogawa N, Kushima I, Suyama S, Saito T, Hamada J, Kano Y, Honda N, Kikuchi S, Seto M, Tomita H, Miyoshi N, Matsumoto M, Kawaguchi Y, Kanai K, Ikeda M, Nakamura I, Isomura S, Hirano Y, Onitsuka T, Ozaki N, Kosaka H, Okada T, Kuwabara H, Yamasue H. Oxytocin-induced increases in cytokines and clinical effect on the core social features of autism: Analyses of RCT datasets. Brain Behav Immun. 118: 398–407, 2024.
20) Onitsuka T: Advancing PTSD treatment: a novel approach in treatment-resistant childhood sexual abuse PTSD. Psychiatry Clin Neurosci, 78: 1, 2024.
21) Onitsuka T: Introduction of the Special Issue on “Neurophysiology/Neuroimaging Study in Japan.” Clin EEG Neurosci, 54: 559, 2023.
22) Okada N, Fukunaga M, Miura K, Nemoto K, Matsumoto J, Hashimoto N, Kiyota M, Morita K, Koshiyama D, Ohi K, Takahashi T, Koeda M, Yamamori H, Fujimoto M, Yasuda Y, Hasegawa N, Narita H, Yokoyama S, Mishima R, Kawashima T, Kobayashi Y, Sasabayashi D, Harada K, Yamamoto M, Hirano Y, Itahashi T, Nakataki M, Hashimoto RI, Tha KK, Koike S, Matsubara T, Okada G, van Erp TGM, Jahanshad N, Yoshimura R, Abe O, Onitsuka T, Watanabe Y, Matsuo K, Yamasue H, Okamoto Y, Suzuki M, Turner JA, Thompson PM, Ozaki N, Kasai K, Hashimoto R. Subcortical volumetric alterations in four major psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification. Mol Psychiatry. 28: 5206–5216, 2023.
23) Matsumoto J, Fukunaga M, Miura K, Nemoto K, Okada N, Hashimoto N, Morita K, Koshiyama D, Ohi K, Takahashi T, Koeda M, Yamamori H, Fujimoto M, Yasuda Y, Ito S, Yamazaki R, Hasegawa N, Narita H, Yokoyama S, Mishima R, Miyata J, Kobayashi Y, Sasabayashi D, Harada K, Yamamoto M, Hirano Y, Itahashi T, Nakataki M, Hashimoto RI, Tha KK, Koike S, Matsubara T, Okada G, Yoshimura R, Abe O, van Erp TGM, Turner JA, Jahanshad N, Thompson PM, Onitsuka T, Watanabe Y, Matsuo K, Yamasue H, Okamoto Y, Suzuki M, Ozaki N, Kasai K, Hashimoto R. Cerebral cortical structural alteration patterns across four major psychiatric disorders in 5549 individuals. Mol Psychiatry. 28: 4915–4923, 2023.
24) Matsumoto R, Motomura E, Onitsuka T, Okada M. Trends in suicidal mortality and motives among working-ages individuals in Japan during 2007–2022. Eur J Investig Health Psychol Educ. 13: 2795–2810, 2023.
25) Onitsuka T, Okada T, Hasegawa N, Tsuboi T, Iga JI, Yasui-Furukori N, Yamada N, Hori H, Muraoka H, Ohi K, Ogasawara K, Ochi S, Takeshima M, Ichihashi K, Fukumoto K, Iida H, Yamada H, Furihata R, Makinodan M, Takaesu Y, Numata S, Komatsu H, Hishimoto A, Kido M, Atake K, Yamagata H, Kikuchi S, Hashimoto N, Usami M, Katsumoto E, Asami T, Kubota C, Matsumoto J, Miura K, Hirano Y, Watanabe K, Inada K, Hashimoto R. Combination psychotropic use for schizophrenia with long-acting injectable antipsychotics and oral antipsychotics: a nationwide real-world study in Japan. J Clin Psychopharmacol. 43: 365–368, 2023.
26) Nakanishi S, Tamura S, Hirano S, Takahashi J, Kitajima K, Takai Y, Mitsudo T, Togao O, Nakao T, Onitsuka T, Hirano Y. Abnormal phase entrainment of low- and high-gamma-band auditory steady-state responses in schizophrenia. Front Neurosci. 17: 1277733, 2023.
27) Hashimoto N, Yasui-Furukori N, Hasegawa N, Ishikawa S, Hori H, Iida H, Ichihashi K, Miura K, Matsumoto J, Numata S, Kodaka F, Furihata R, Ohi K, Ogasawara K, Iga JI, Muraoka H, Komatsu H, Takeshima M, Atake K, Kido M, Nakamura T, Kishimoto T, Hishimoto A, Onitsuka T, Okada T, Ochi S, Nagasawa T, Makinodan M, Yamada H, Tsuboi T, Yamada H, Inada K, Watanabe K, Hashimoto R: Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project. BMC Psychiatry, 23: 473, 2023.
28) Fukumoto K, Kodaka F, Hasegawa N, Muraoka H, Hori H, Ichihashi K, Yasuda Y, Iida H, Ohi K, Ochi S, Ide K, Hashimoto N, Usami M, Nakamura T, Komatsu H, Okada T, Nagasawa T, Furihata R, Atake K, Kido M, Kikuchi S, Yamagata H, Kishimoto T, Makinodan M, Horai T, Takeshima M, Kubota C, Asami T, Katsumoto E, Hishimoto A, Onitsuka T, Matsumoto J, Miura K, Yamada H, Yasui-Furukori N, Watanabe K, Inada K, Otsuka K, Hashimoto R: Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood Disorders. Neuropsychopharmacol Rep, 43: 33-39, 2023.
29) Iida H, Okada T, Nemoto K, Hasegawa N, Numata S, Ogasawara K, Miura K, Matsumoto J, Hori H, Iga JI, Ichihashi K, Hashimoto N, Yamada H, Ohi K, Yasui-Furukori N, Fukumoto K, Tsuboi T, Usami M, Furihata R, Takaesu Y, Hishimoto A, Muraoka H, Katsumoto E, Nagasawa T, Ochi S, Komatsu H, Kikuchi S, Takeshima M, Onitsuka T, Tamai S, Kubota C, Inada K, Watanabe K, Kawasaki H, Hashimoto R: Satisfaction with web-based courses on clinical practice guidelines for psychiatrists: Findings from the "Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)" project. Neuropsychopharmacol Rep, 43: 23-32, 2023.
30) Kitajima K, Tamura S, Sasabayashi D, Nakajima S, Iwata Y, Ueno F, Takai Y, Takahashi J, Caravaggio F, Mar W, Torres-Carmona E, Noda Y, Gerretsen P, Luca V, Mimura M, Hirano S, Nakao T, Onitsuka T, Remington G, Graff-Guerrero A, Hirano Y: Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment-resistant and ultra-treatment-resistant schizophrenia. Psychiatry Clin Neurosci, 77: 2-11, 2023.
31) Onitsuka T, Tsuchimoto R, Oribe N, Spencer KM, Hirano Y: Neuronal imbalance of excitation and inhibition in schizophrenia: a scoping review of gamma-band ASSR findings. Psychiatry Clin Neurosci, 76: 610-619, 2022.
32) Onitsuka T, Hirano Y, Nakazawa T, Ichihashi K, Miura K, Inada K, Mitoma R, Yasui-Furukori N, Hashimoto R: Current concepts, findings, and future research directions toward recovery in schizophrenia. Psychiatry Clin Neurosci, 76: 282-291, 2022.
33) Onitsuka T, Hirano Y, Nemoto K, Hashimoto N, Kushima I, Koshiyama D, Koeda M, Takahashi T, Noda Y, Matsumoto J, Miura K, Nakazawa T, Hikida T, Kasai K, Ozaki N, Hashimoto R: Trends in big data analyses by multicenter collaborative translational research in psychiatry. Psychiatry Clin Neurosci, 76: 1-14, 2022.
34) Tamura S, Hirose N, Mitsudo T, Hoaki N, Nakamura I, Onitsuka T, Hirano Y: Multimodal imaging of the auditory-larynx motor network for voicing perception. NeuroImage, 251:118981. doi: 10.1016/j.neuroimage.2022.118981. 2022.
35) Okamoto H, Onitsuka T, Kuga H, Oribe N, Nakayama N, Fukushima S, Nakao T, Ueno T: Decreased BOLD signals elicited by 40-Hz auditory stimulation of the right primary auditory cortex in bipolar disorder: An fMRI study. Front Psychiatry, 13: 833896, 2022.
36) Yamasue H, Kojima M, Kuwabara H, Kuroda M, Matsumoto K, Kanai C, Inada N, Owada K, Ochi K, Ono N, Benner S, Wakuda T, Kameno Y, Inoue J, Harada T, Tsuchiya K, Umemura K, Yamauchi A Ogawa N, Kushima I, Ozaki N, Suyama S, Saito T, Uemura Y, Kano Y, Honda N, Kikuchi S, Seto M, Tomita H, Miyoshi N, Matsumoto M, Kawaguchi Y, Kanai K, Ikeda M, Nakamura I, Isomura S, Hirano Y, Onitsuka T, Kosaka H, Okada T: Effect of a novel nasal oxytocin spray with enhanced bioavailability on autism: A randomised trial. Brain, 145: 490-499, 2022.
37) Yasui-Furukori N, Muraoka H, Hasegawa N, Ochi S, Numata S, Hori H, Hishimoto A, Onitsuka T, Ohi K, Hashimoto N, Nagasawa T, Takaesu Y, Inagaki T, Tagata H, Tsuboi T, Kubota C, Furihata R, Iga J, Iida H, Miura K, Matsumoto J, Yamada H, Watanabe K, Inada K, Shimoda K, Hashimoto R. Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep, 42:3-9, 2022.
38) Ogasawara K, Numata S, Hasegawa N, Nakataki M, Makinodan M, Ohi K, Takeshima M, Tsuboi T, Hashimoto N, Onitsuka T, Muraoka H, Hori H, Ichihashi K, Inagaki T, Yasui-Furukori N, Hishimoto A, Sugiyama N, Fukumoto K, Nagasawa T, Matsumoto J,Takaesu Y, Furihata R, Nemoto K, Nakamura T, Usami M, Miura K, Fujimoto M,Tagata H, Yamada H, Komatsu H, Ochi S, Atake K, Katsumoto E, Kido M, Kishimoto T, Suwa T, Yamamura S, Iga JI, Iida H, Inada K, Watanabe K, Hashimoto R. Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. Neuropsychopharmacol Rep, 42: 221-225, 2022.
39) Kyou Y, Yasui-Furukori N, Hasegawa N, Ide K, Ichihashi K, Hashimoto N, Hori H, Shimizu Y, Imamura Y, Muraoka H, Iida H, Ohi K, Yasuda Y, Ogasawara K, Numata S, Iga JI, Tsuboi T, Ochi S, Kodaka F, Furihata R, Onitsuka T, Makinodan M, Komatsu H, Takeshima M, Kubota C, Hishimoto A, Atake K, Yamagata H, Kido M, Nagasawa T, Usami M, Kishimoto T, Kikuchi S, Matsumoto J, Miura K, Yamada H, Watanabe K, Inada K, Hahimoto R. The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)" project. Ann Gen Psychiatry. 26;21(1):52, 2022.
40) Yamada H, Motoyama M, Hasegawa N, Miura K, Matsumoto J, Ohi K, Yasui-Furukori N, Numata S, Takeshima M, Sugiyama N, Nagasawa T, Kubota C, Atake K, Tsuboi T, Ichihashi K, Hashimoto N, Inagaki T, Takaesu Y, Iga JI, Hori H, Onitsuka T, Komatsu H, Hishimoto A, Fukumoto K, Fujimoto M, Nakamura T, Nemoto K, Furihata R, Yamamura S, Yamagata H, Ogasawara K, Katsumoto E, Murata A, Iida H, Ochi S, Makinodan M, Kido M, Kishimoto T, Yasuda Y, Usami M, Suwa T, Inada K, Watanabe K, Hashimoto R: A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project. BJPsych Open, 8: e83, 2022.
41) Hori H, Yasui-Furukori N, Hasegawa N, Iga J, Ochi S, Ichihashi K, Furihata R, Kyo Y, Takaesu Y, Tsuboi T, Kodaka F, Onitsuka T, Okada T, Murata A, Kashiwagi H, Iida H, Hashimoto N, Ohi K, Yamada H, Ogasawara K, Yasuda Y, Muraoka H, Usami M, Numata S, Takeshima M, Yamagata H, Nagasawa T, Tagata H, Makinodan M, Kido M, Katsumoto E, Komatsu H, Matsumoto J, Kubota C, Miura K, Hishimoto A, Watanabe K, Inada K, Kawasaki H, Hashimot R. Prescription of anticholinergic drugs in patients with schizophrenia: analysis of antipsychotic prescription patterns and hospital characteristics. Front Psychiatry, 13: 823826, 2022.
42) Muraoka H, Kodaka F, Hasegawa N, Yasui-Furukori N, Fukumoto K, Kashiwagi H, Tagata H, Hori H, Atake K, Iida H, Ichihashi K, Furihata R, Tsuboi T, Takeshima M, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Makinodan M, Nakamura T, Kido M, Ueda I, Yamagata H, Onitsuka T, Asami T, Hishimoto A, Ogasawara K, Katsumoto E, Miura K, Matsumoto J, Ohi K, Yamada H, Watanabe K, Inada K, Nishimura K, Hashimoto R. Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site study. Asian J Psychiatry, 74:103174, 2022.
43) Furihata R, Otsuki R, Hasegawa N, Tsuboi T, Numata S, Yasui-Furukori N, Kashiwagi H, Hori H, Ochi S, Muraoka H, Onitsuka T, Komatsu H, Takeshima M, Hishimoto A, Nagasawa T, Takaesu Y, Nakamura T, Asami T, Miura K, Matsumoto J, Ohi K, Yasuda Y, Iida H, Ogasawara K, Hashimoto N, Ichihashi K, Yamada H, Watanabe K, Inada K, Hashimoto R. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study. Sleep Med, 89:23-30, 2021.
44) Sato J, Hirano Y, Hirakawa N, Takahashi J, Oribe N, Kuga H, Nakamura I, Hirano S, Ueno T, Togao O, Hiwatashi A, Nakao T, Onitsuka T: Lower hippocampal volume in patients with schizophrenia and bipolar disorder: a quantitative MRI study. J Pers Med. 13: 11, 121, 2021.
45) Takahashi J, Hirano Y, Miura K, Morita K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Shishido E, Okazaki K, Shiino T, Nakao T, Kasai K, Hashimoto R, Onitsuka T: Eye movement abnormalities in major depressive disorder. Front Psychiatry. 2021 10: 12, 673443, 2021.
46) Takahashi J, Miura K, Morita K, Fujimoto M, Miyata S, Okazaki K, Matsumoto J, Hasegawa N, Hirano Y, Yamamori H, Yasuda Y, Makinodan M, Kasai K, Ozaki N, Onitsuka T, Hashimoto R: Effects of age and sex on the eye movement characteristics. Neuropsychopharmacol Rep, 41: 152-158, 2021.
47) Numata S, Nakataki M, Hasegawa N, Takaesu Y, Takeshima M, Onitsuka T, Nakamura T, Edagawa R, Edo H, Miura K; Matsumoto J, Yasui-Furukori N, Kishimoto T; Hori H, Tsuboi T, Yasuda Y, Furihata R, Muraoka H, Ochi S, Nagasawa T; Kyou T, Murata A, Katsumoto E, Ohi K, Hishimoto A, Inada K, Watanabe K, Hashimoto R: Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep. 41: 199-206, 2021.